Image

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Research on adding Tarlatamab to Durvalumab for specific lung cancer treatment.

Recruiting
18-99 years
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study looks at how well two drugs, tarlatamab and durvalumab, work together compared to durvalumab alone for treating a type of lung cancer called extensive-stage small-cell lung cancer (ES-SCLC). Participants should be adults who have already had some chemotherapy and are stable without disease progression. They must have a life expectancy of at least 12 weeks and meet other health criteria.

  • Length and Visits: The study requires completing all visits and procedures as outlined.
  • Compensation: Information on compensation is not provided, check with the study team.
  • Risks: There may be risks from the study drugs or procedures, discuss these with the study doctor.

Some people cannot join the study, such as those with certain health conditions like brain problems or recent heart issues. Women who are pregnant, breastfeeding, or planning to become pregnant cannot join. Men should agree to certain conditions if their partner can become pregnant. This study will help find better ways to treat this lung cancer, but participants should discuss with their doctor to know if it's right for them.

Print
Study details
    Extensive-Stage Small-Cell Lung Cancer
    Small-Cell Lung Cancer

NCT06211036

Amgen

28 June 2025

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.